Accelerating Biotech Innovation: From Hit to Optimized Lead with Oxeltis

At Oxeltis, we recognize the pressures biotechs face in turning promising biological insights into scalable, investor-ready drug candidates. Our mission is to empower biotechs with the expertise, speed, and integrated solutions required to de-risk your pipeline and accelerate the path to clinical success.

01 — YOUR CHALLENGES

The challenges biotechs face

Fume hoods and rotary evaporator in the Oxeltis laboratory

The journey from hit identification to clinical candidate is often stalled by a lack of in-house chemistry capacity, slowing programs at the critical Hit-to-Lead stage.

Coordinating multiple CROs across chemistry, computation, and biology produces inconsistent datasets that are difficult to present coherently to investors and partners.

Without comprehensive, decision-ready preclinical data, securing funding or attracting pharma partners becomes significantly harder and timelines extend.

Biotechs need fast DMTA cycles without compromising on data quality or regulatory readiness, a balance that generic CROs are rarely set up to deliver.

02 — HOW WE HELP

Tailored solutions for biotechs: from early hits to investor-ready leads

An integrated Hit-to-Lead platform: chemistry, computation, and biology

We specialize in transforming early-stage small molecule programs into high-potential leads by combining computational design (CADD, SBDD, LBDD, AI/ML via Molecular Forecaster), precision synthesis, and rigorous biological validation (assay development and in vitro screening via Partex.AI Labs). One team. One point of contact. No coordination overhead.

PhD-level chemistry team delivering high-purity compounds rapidly

Our team, composed of 50% PhD and 50% MSc chemists, delivers high-purity compounds with the speed needed to validate mechanisms, generate robust preclinical data, and meet investor requirements. Specializing in complex chemistry such as chiral separations and novel synthetic routes, our SFC purification platform scales efficiently up to 25 g/day.

03 — YOUR DEDICATED TEAM

One team leader. One point of contact.

With Oxeltis, you don't just outsource, you co-develop with a team that understands the unique pressures of biotech innovation, from seed funding to clinical entry. A dedicated project leader coordinates all chemistry, computational, and biological workstreams across the Oxeltis consortium, providing proactive updates, transparent communication, and no hidden coordination costs.

Our 15+ years in medicinal chemistry, combined with agile, partnership-driven execution, make us the ideal collaborator for biotechs aiming to validate mechanisms with in vitro and in silico evidence, optimize leads for potency, selectivity, and developability, and secure partnerships with pharma or investors through compelling, reproducible results.

04 — RELEVANT SERVICES FOR BIOTECHS

Services most relevant to Biotechs

Smiling Oxeltis chemist at her workstation

Rapidly transform your validated hits into optimized leads, with dedicated PhD-level chemists acting as your external medicinal chemistry team, fully integrated with your biology and SAR data.

Physics-based computational prioritization via Molecular Forecaster reduces the number of compounds synthesized by 30–50%, stretching your chemistry budget further and accelerating decision cycles.

In vitro bioactivity assays (via Partex.AI Labs) and early pharmacology producing the comprehensive, investor-grade datasets your pipeline needs to progress confidently.

From challenging single analogs to gram-scale preclinical batches, full analytical documentation, and SFC purification up to 25 g/day.

Ready to turn your scientific hypotheses into clinical candidates?

Let's discuss how we can tailor our expertise to your pipeline with the rigor your stakeholders demand.